trending Market Intelligence /marketintelligence/en/news-insights/trending/x1Jv-j-v3WsU4-nI51UJ7g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Nabriva Therapeutics seeks US FDA approval for pneumonia treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Nabriva Therapeutics seeks US FDA approval for pneumonia treatment

Nabriva Therapeutics PLC has submitted its antibiotic treatment for a type of bacterial pneumonia to the U.S. Food and Drug Administration for approval.

Ireland-based Nabriva said in a Dec. 20 press release that a new drug application for the oral and intravenous formulations of lefamulin has been submitted to the U.S. regulator to treat community-acquired bacterial pneumonia. Both formulations of the antibiotic have been granted qualified infectious disease product and fast track designation by the FDA, which means the medicine could be up for a priority review.

Community-acquired bacterial pneumonia affects more than 5 million adults a year in the U.S., according to data analyzed by Nabriva.

The FDA submission is supported by phase 3 clinical trials that evaluated lefamulin compared to moxifloxacin, a common antibiotic treatment for pneumonia. The trial showed that lefamulin is similarly effective to moxifloxacin.

The company will also seek marketing authorization for lefamulin in the EU, with plans to submit its application in the first quarter of 2019.

Nabriva is a clinical-stage biopharmaceutical company that develops anti-infective agents to treat infections in humans.